Drug Discovery World

MARCH 12, 2024

DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. Amanda Halford, President Bioprocess, Cytiva “In 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates. This is part of a series of predictions based on different themes.

Molecular Biology 204

Molecular Biology Small Molecule Therapies FDA Approval 204

Drug Discovery World

MAY 1, 2024

DDW’s Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024. Artificial intelligence (AI) AI is on everyone’s minds as we head into 2024; of course, this is across not just the drug discovery spectrum but is particularly relevant to therapeutic antibodies.

FDA Approval 147

FDA Approval Therapies FDA Molecular Biology 147

Drug Discovery World

MARCH 12, 2024

MJ : From the first known reference to medicinal use of plants on a Mesoptamian clay tablet written during the third millennium BC to the FDA approval of the blockbuster anticancer drug Taxol in the 1990s, natural products from plants have been at the forefront of efforts to overcome human diseases, such as cancers, hypertension, and pain.

Small Molecule 147

Small Molecule Synthetic Chemistry Production Molecular Biology 147

Drug Discovery World

DECEMBER 26, 2023

Makoto Inoue, President and Representative Director of Otsuka Pharmaceutical commented: “Otsuka is committed to the development of drugs for rare diseases such as autosomal dominant polycystic kidney disease (ADPKD). This agreement is aligned with our strategy to initially focus our commercialisation efforts on the US market.

Small Molecule 130

Small Molecule Drugs Molecular Biology Bioinformatics 130

LifeSciVC

AUGUST 5, 2024

But that initial quote isn’t from 2024, it is from an interview in 2021 with Mark Levin, CEO at Millennium (MIT Technology Review). In fact, it increased the requirement for experienced biologists to use the new genomic information and combine it with mechanistic biology to derive new therapeutic insights. One final parallel to 2001.

Molecular Biology 88

Molecular Biology Production Small Molecule Drug Development 88

Drug Discovery World

APRIL 30, 2024

Whilst research into mRNA has been ongoing for decade, interest has sparked in recent years and research has begun to expand into areas of vaccinology, infectious diseases and other indications. If the body fails to make the right protein, diseases such as cancer, type II diabetes, neurological conditions, and metabolic diseases can occur.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Elrig

APRIL 29, 2024

Fascinated by the potential of AI in medical research, I transitioned to BenevolentAI in early 2023 as a Biology Project Leader. There, I supported AI-enabled DD efforts in their small molecule portfolio. Joining Isomorphic Labs in October 2024, I’m thrilled to be part of their mission to revolutionize DD through AI/ML.

Bioinformatics 59

Bioinformatics Molecular Biology Drugs Cell Based Assays 59